Stimate
Acne Vulgaris, moderate Vulvovaginal atrophy, Hot flashes + 9 more
Treatment
9 FDA approvals
20 Active Studies for Stimate
Treatment for
Acne Vulgaris
What is Stimate
Norgestimate
The Generic name of this drug
Treatment Summary
Norgestimate is a medication used in combination with ethinylestradiol to form an oral contraceptive that was developed in 1977. This combined contraceptive can also be used to treat moderate acne. Norgestimate was officially approved by the FDA in December 1989.
Ortho Tri Cyclen
is the brand name
Stimate Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Ortho Tri Cyclen
Norgestimate
1989
113
Approved as Treatment by the FDA
Norgestimate, commonly known as Ortho Tri Cyclen, is approved by the FDA for 9 uses which include Postmenopausal Osteoporosis and severe menopausal vulvovaginal atrophy .
Postmenopausal Osteoporosis
Used to treat Postmenopausal Osteoporosis in combination with Estradiol
severe menopausal vulvovaginal atrophy
Used to treat severe menopausal vulvovaginal atrophy in combination with Estradiol
Oral Contraceptives
Used to treat Oral Contraceptives in combination with Ethinylestradiol
Acne Vulgaris
Used to treat moderate Acne vulgaris in combination with Ethinylestradiol
Osteoporosis, Postmenopausal
Used to treat Postmenopausal Osteoporosis in combination with Estradiol
moderate Vulvovaginal atrophy
Used to treat moderate Vulvovaginal atrophy in combination with Estradiol
Hot flashes
Used to treat Menopause in combination with Estradiol
moderate Menopausal Vasomotor Symptoms
Used to treat moderate Menopausal Vasomotor Symptoms in combination with Estradiol
Menopause
Used to treat severe Vasomotor Symptoms Associated With Menopause in combination with Estradiol
Effectiveness
How Stimate Affects Patients
Norgestimate is a contraceptive and acne treatment as it stops ovulation and reduces the amount of testosterone in the body. It is considered to be a safe drug, but patients should be aware of the potential risks such as vascular and liver disease, high blood pressure, changes in metabolism, headaches, and irregular bleeding.
How Stimate works in the body
Norgestimate, a type of progesterone hormone, works by decreasing the amount of hormone released by the brain that stimulates ovulation and testosterone production. This decrease in hormone levels reduces the amount of testosterone available in the body, which in turn helps to reduce symptoms of acne.
When to interrupt dosage
The recommended amount of Stimate relies on the diagnosed condition, including Hypermenorrhea, Postmenopausal Osteoporosis and Menstrual Distress (Dysmenorrhea). The measure of dosage depends on the mode of administration (e.g. Kit or Kit - Oral) as indicated in the table below.
Condition
Dosage
Administration
Polycystic Ovarian Syndrome
, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg
Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral
moderate Vulvovaginal atrophy
, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg
Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral
severe menopausal vulvovaginal atrophy
, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg
Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral
Menopause
, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg
Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral
Osteoporosis, Postmenopausal
, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg
Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral
Oral Contraceptives
, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg
Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral
Menorrhagia
, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg
Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral
Hirsutism
, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg
Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral
moderate Menopausal Vasomotor Symptoms
, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg
Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral
Hot flashes
, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg
Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral
Acne Vulgaris
, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg
Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral
Dysmenorrhea
, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg
Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral
Warnings
Stimate has eleven proscribed contraindications and must not be utilized when experiencing any of the conditions given in the following table.
Stimate Contraindications
Condition
Risk Level
Notes
Breast
Do Not Combine
Breast Cancer
Do Not Combine
high risk of arterial thrombotic disease
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Hypersensitivity
Do Not Combine
Venous Thrombosis
Do Not Combine
Pulse Frequency
Do Not Combine
estrogen-sensitive cancer
Do Not Combine
Metrorrhagia
Do Not Combine
Liver Neoplasms
Do Not Combine
There are 20 known major drug interactions with Stimate.
Common Stimate Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The serum concentration of Abemaciclib can be increased when it is combined with Norgestimate.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be increased when combined with Norgestimate.
Alectinib
Major
The metabolism of Alectinib can be increased when combined with Norgestimate.
Aminophylline
Major
The metabolism of Aminophylline can be increased when combined with Norgestimate.
Astemizole
Major
The metabolism of Astemizole can be increased when combined with Norgestimate.
Stimate Toxicity & Overdose Risk
Overdosing on norgestimate is rare, but those who do may require symptomatic and supportive care. Most people who overdose on oral contraceptives do not experience serious harm.
Stimate Novel Uses: Which Conditions Have a Clinical Trial Featuring Stimate?
30 active trials are being conducted to examine the potential of Stimate in treating Postmenopausal Osteoporosis, moderate Vulvovaginal atrophy and Menopausal symptoms.
Condition
Clinical Trials
Trial Phases
Dysmenorrhea
1 Actively Recruiting
Not Applicable
Acne Vulgaris
0 Actively Recruiting
Osteoporosis, Postmenopausal
0 Actively Recruiting
Oral Contraceptives
1 Actively Recruiting
Not Applicable
Menopause
0 Actively Recruiting
Polycystic Ovarian Syndrome
7 Actively Recruiting
Not Applicable, Phase 1
moderate Menopausal Vasomotor Symptoms
0 Actively Recruiting
Hirsutism
0 Actively Recruiting
Hot flashes
19 Actively Recruiting
Not Applicable, Phase 2, Phase 4, Early Phase 1, Phase 3
moderate Vulvovaginal atrophy
0 Actively Recruiting
Menorrhagia
3 Actively Recruiting
Phase 1, Phase 2, Not Applicable
severe menopausal vulvovaginal atrophy
0 Actively Recruiting
Stimate Reviews: What are patients saying about Stimate?
4.3
Patient Review
5/1/2017
Stimate for Blood Clotting Disorder - Von Willebrand's Disease
4.3
Patient Review
7/28/2014
Stimate for Blood Clotting Disorder - Von Willebrand's Disease
4.3
Patient Review
3/16/2008
Stimate for Blood Clotting Disorder - Von Willebrand's Disease
4
Patient Review
10/8/2012
Stimate for Blood Clotting Disorder - Von Willebrand's Disease
4
Patient Review
3/20/2010
Stimate for Blood Clotting Disorder - Von Willebrand's Disease
4
Patient Review
9/8/2008
Stimate for Blood Clotting Disorder - Von Willebrand's Disease
3.7
Patient Review
1/22/2011
Stimate for Blood Clotting Disorder - Von Willebrand's Disease
3.7
Patient Review
11/11/2010
Stimate for Blood Clotting Disorder - Von Willebrand's Disease
3
Patient Review
9/28/2009
Stimate for Blood Clotting Disorder - Von Willebrand's Disease
Patient Q&A Section about stimate
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is there a generic for Stimate?
"The prescription drug Stimate is not currently available in a generic form in the United States."
Answered by AI
Why was Stimate discontinued?
"Ferring Pharmaceuticals has issued a recall of the Stimate (desmopressin) nasal spray due to it containing higher amounts of desmopressin than specified. Stimate is used to treat von Willebrand disease (VWD) and mild hemophilia A."
Answered by AI
Is Stimate still available?
"The product is available in 31 states and can be purchased from STAQ by any pharmacy. NHF, HFA, and the Hemophilia Alliance are working with STAQ to get the product licensed in all 50 states."
Answered by AI